NEW YORK (GenomeWeb) — Cepheid said last week that its third quarter revenues grew 15 percent year over year driven primarily by stronger than expected commercial clinical revenue resulting from new Xpert assays and customer types.
Specifically, the company disclosed that in Q3 it landed as customers two major US reference labs that, taken together, are expected to eventually account for some half a million Xpert tests annually.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
